Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
WHO urges Taliban to lift restrictions on female aid workers after deadly quake
- 6 hours ago
SC adopts Supreme Court Rules 2025
- 5 hours ago
Pakistan Navy Day being observed to honour heroes of 1965 war
- 8 hours ago
Fatal collision in Karachi: Motorcyclist dies after being hit by speeding trailer
- 3 hours ago
Will Karachi schools remain open tomorrow?
- 5 hours ago
IAEA chief reports progress in Iran nuclear talks
- 3 hours ago
10 dead, 87 injured as protests erupt in Nepal over corruption, social media ban
- 7 hours ago
French parliament topples Bayrou government after just 9 months
- 3 hours ago
Pakistan’s pharma exports reach $457m
- 3 hours ago
Overseas Pakistanis send $3.1bn worth of remittances in August
- 7 hours ago
Floods are a result of our sins: Nida Chaudhry
- 7 hours ago
US firm inks MoU with Pakistan’s FWO on critical minerals
- 7 hours ago
